Cancer-associated prothrombotic effects include the hematogenous release of cancer-derived microparticles that trigger the coagulation cascade, production of procoagulant factors such as factor X, release of mucins that activate platelets and endothelial cells through the binding of P-selectin, and stimulation of neutrophils to release decondensed chromatin that forms prothrombotic neutrophil extracellular traps [5,6,7]. Here, F10 is linked to cancer.